In contrast to our study [17], patients were enrolled more than 15 years ago in the study by Sin et al. [1], and, therefore, did not routinely receive modern heart failure therapy including β-blockers or aldosterone antagonists in addition to angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). The gene discussed is ACE; the disease is heart failure.